W temacie pracy o amantadynie nature.com/articles/s4200…
praca powołuje się na "All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study" ncbi.nlm.nih.gov/pmc/articles/P…
a w niej czytamy we wnioskach:
no ale jedziemy dalej. druga to "Rejdak, K. & Grieb, P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment"
następna:Jefferson, T., Demicheli, V., Deeks, J. & Rivetti, D. Amantadine and rimantadine for preventing and treating influenza A in adults (chyba nie bardzo na temat SARS-CoV2)
następna: Crosby, N. J., Deane, K. & Clarke, C. E. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database Syst. Rev
kolejna praca: Aranda-Abreu, G. E. et al. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol. Rep
następni mówią: Fink, K. et al. Amantadine inhibits sars-cov-2 in vitro
ncbi.nlm.nih.gov/pmc/articles/P… na szkiełku
pozostałe to influenza i ani słowa o SARS-CoV2
Tak więc
gdzie te rekomendacje? oparte na pracy z 22 czy 15 pacjentami?
@threadreaderapp unroll
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.